Source comparison
BPC-157 vs TB-500: Research Peptide Comparison
BPC-157 VEGF-mediated angiogenesis + collagen synthesis Tendon/ligament tears, gut inflammation, localized tissue damage ~4 hours (frequent dosing required) 250–500 mcg daily, injected near injury site or oral for GI First-line for structural connective tissue
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF-mediated angiogenesis + collagen synthesis
- Tendon/ligament tears, gut inflammation, localized tissue damage
- ~4 hours (frequent dosing required)
- 250–500 mcg daily, injected near injury site or oral for GI
- First-line for structural connective tissue injuries where vascularization is the limiting factor. No substitute for hypovascular repair
- TB-500
- G-actin sequestration + systemic immune modulation
- Muscle strains, post-surgical recovery, chronic systemic inflammation
- 7–10 days (weekly dosing sufficient)
- 2–5 mg weekly, subcutaneous administration
- Superior for diffuse muscle damage and systemic recovery. The longer half-life makes compliance easier than BPC-157's daily requirement
- Combined Protocol
- Dual-pathway activation (local + systemic)
- Complex injuries with both structural and inflammatory components
- Varies by compound
- BPC-157 daily + TB-500 weekly
- Synergistic in theory, supported by limited human data. Most evidence is observational rather than controlled trial